Myriad genetics Logo (EUIPO, 10/20/2021)
EUIPOProtect this trademark from copycats!
With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.
The Union trademark Myriad genetics was filed as Figurative mark on 10/20/2021 at the European Union Intellectual Property Office.
It was registered as a trademark on 05/20/2022.
The current status of the mark is "Trademark registered".
Logodesign (Wiener Klassifikation)
#Letters presenting a special form of writing
| Trademark form | Figurative mark |
| File reference | 018581769 |
| Application date | October 20, 2021 |
| Publication date | February 10, 2022 |
| Entry date | May 20, 2022 |
| Expiration date | October 20, 2031 |
Trademark owner
320 Wakara Way
84108 Salt Lake City
US
84108 Salt Lake City
US
Trademark representatives
Kungsbroplan 3
112 27 Stockholm
SE
goods and services
5
Medical test kits comprising chemical reagents and preparations for medical use in connection with the detection of gene mutations, gene expression profiles, and other molecular abnormalities, indicators, and markers for use in prognosing or predicting progression and severity of disease and predisposition to developing disease and for use in evaluating and selecting therapy or treatment regimens; medical diagnostic reagents, assays, preparations, and diagnostic test kits consisting primarily of reagents for medical diagnostic purposes, namely, testing of fluids; chemical reagents for medical use in connection with the detection of gene mutations, gene expression profiles, and other molecular abnormalities, indicators, and markers for use in prognosing or predicting progression and severity of disease and predisposition to developing disease and for use in evaluating and selecting therapy or treatment regimens; diagnostic test kits comprised of chemical reagents and preparations for medical use in connection with the detection of gene mutations, gene expression profiles, and other molecular abnormalities, indicators, and markers for use in prognosing or predicting progression and severity of disease and predisposition to developing disease and for use in evaluating and selecting therapy or treatment regimens; diagnostic kits consisting primarily of reagents for body fluid analysis and nucleic acid analysis and for detecting genetic conditions, disorders, and diseases for medical use
10
Medical test kits comprising test forms, mailing materials, user information inserts, and specimen collection tubes and containers for collecting patient specimens used in connection with the detection of gene mutations, gene expression profiles, and other molecular abnormalities, indicators, and markers for use in prognosing or predicting progression and severity of disease and predisposition to developing disease and for use in evaluating and selecting therapy or treatment regimens; sample preparation device for medical diagnostic uses; medical apparatus and instruments for diagnostic use, namely, apparatus for medical diagnostic testing in the fields of tissue-based diagnostic testing, cytology and cell-based testing; blood, urine, and saliva collection kits consisting of test tubes and selfmailer used for health and genetic analysis and diagnostics
42
Clinical research in the field of genetics directed to the evaluation of genetic variants; clinical research in human genetics; statistical analysis relating to scientific research in the field of human genetics and genetic variation; design and development of statistical algorithms for use in the field of human genetics and evaluation of genetic variations; statistical analysis for determining deleterious genetic variations in the field of human genetics, for scientific research purposes; clinical trial research and laboratory research services for the further purpose of drug discovery services, pharmaceutical research services, pre-clinical medical research screening, and clinical trial, research and evaluation services; biosignatures, genomics, proteomics and pharmacology research services; development of disease models for use in evaluation of drugs and discovery of new drugs; drug discovery, drug screening for scientific research purposes, pre-clinical research and trials for pharmaceutical development purposes; and research and development of new diagnostic products and pharmaceutical drug services for others; biochemical analysis services, namely, evaluation of non-genetic biological response to disease, drugs, and the environment; providing temporary use of non-downloadable computer software for customizing, selecting, and ordering health and genetic analysis and diagnostic kits and assays and for accessing, viewing, and storing health and genetic information via electronic, optical, and wireless communication networks; scientific research analysis and consulting services which use bioinformatics
44
Genetic testing services; genetic testing for medical purposes; genetic counseling; diagnostic services in the field of genetics, namely, the identification of genes that predispose individuals to common diseases and health disorders; medical testing, namely, providing reference and clinical laboratory tests that detect, classify, analyze, and evaluate gene mutations, gene variants, gene expression profiles, and other molecular abnormalities, indicators, and markers for use in prognosing or predicting progression and severity of disease and for use in evaluating and selecting therapy or treatment regimens; medical testing services for evaluating and selecting therapy or treatment regimens, prognosing disease, predicting disease progression or disease severity, identifying predisposition to developing disease, evaluating the efficacy or toxicity of medical treatments, and identifying risk factors of disease, molecular profiles associated with successful therapies or treatment regimens, and for classifying disease progression or severity; medical diagnostic testing, monitoring, and reporting services; internet-based health care information services; providing an internet website for medical professionals in relation to medical information in the field of hereditary cancer risk assessment and testing; providing personalized healthcare and medical information; providing personalized healthcare and medical information, namely, providing medical information and reports that will enable doctors and clinicians to select and recommend the appropriate treatment, drug, and dosage levels for patients; providing medical information and reports that will enable doctors and clinicians to select and recommend the appropriate treatment, drug, and dosage levels for patients through the use of data obtained through personalized pharmacogenetic testing, proteomics and other biological testing; providing medical information and reports that will enable doctors and clinicians to select and recommend the appropriate treatment, drug, and dosage levels for patients through the use of data obtained through individual behaviors including medication compliance, exercise diet, sleep patterns and language, epigenetic and environmental factors, and bioinformatics analysis; and consultation services related thereto; medical testing services; medical testing services, namely, providing medical tests that measure, analyze, and interpret genes and medications of patients, environmental, and other factors through an algorithm; medical testing services, namely, providing medical tests that measure, analyze, and interpret genes and medications of patients, environmental, and other factors through an algorithm that weighs the contribution of each medication's multiple pathways of absorption, distribution, metabolism, and excretion; medical testing services, namely, providing medical tests that measure, analyze, and interpret genes and medications of patients, environmental, and other factors through an algorithm that weighs the contribution of each medication's receptor activity, mechanism of action, and pathways of response; medical testing services that measure the impact of genomic changes across pathways and across multiple of patients to predict which drugs and/or treatment programs have the best opportunity for positive outcomes for patients, personalize medication/treatment selection, identify potentially harmful drug interactions, and calculate drug dosage adjustments for patients; and medical information services, namely, preparation and generation of reports for the foregoing medical testing services through proprietary software applications; medical analysis and consultation services which use bioinformatics for diagnostic or treatment purposes; providing objective, evidence-based medical information tailored to each patient's individual genetic profile to enable clinicians to prescribe individually appropriate medications; gene and tissue bank services that provide DNA samples for use in future medical and scientific research, medical and scientific educational studies, and development of new medical and scientific products and validation thereof; gene and tissue bank services that provide DNA samples for use in future medical and scientific research, medical and scientific educational studies and development of new medical and scientific products and validation thereof
Trademark history
| Date | Document number | Area | Entry |
|---|---|---|---|
| January 4, 2024 | Change Representative, Published |
ID: 11018581769